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Abstract: Despite being introduced in clinical practice more than 20 years ago, selection criteria for
deep brain stimulation (DBS) in Parkinson’s disease (PD) rely on a document published in 1999
called ‘Core Assessment Program for Surgical Interventional Therapies in Parkinson’s Disease’.
These criteria are useful in supporting the selection of candidates. However, they are both restrictive
and out-of-date, because the knowledge on PD progression and phenotyping has massively evolved.
Advances in understanding the heterogeneity of PD presentation, courses, phenotypes, and genotypes,
render a better identification of good DBS outcome predictors a research priority. Additionally,
DBS invasiveness, cost, and the possibility of serious adverse events make it mandatory to predict as
accurately as possible the clinical outcome when informing the patients about their suitability for
surgery. In this viewpoint, we analyzed the pre-surgical assessment according to the following topics:
early versus delayed DBS; the evolution of the levodopa challenge test; and the relevance of axial
symptoms; patient-centered outcome measures; non-motor symptoms; and genetics. Based on the
literature, we encourage rethinking of the selection process for DBS in PD, which should move toward
a broad clinical and instrumental assessment of non-motor symptoms, quantitative measurement of
gait, posture, and balance, and in-depth genotypic and phenotypic characterization.
Keywords: Parkinson’s disease; deep brain stimulation; selection; levodopa; axial symptoms;
non motor symptoms; genetics
1. Introduction
Despite having being introduced in clinical practice more than 20 years ago, selection criteria
for deep brain stimulation (DBS) as an effective treatment for advanced Parkinson’s disease (PD)
still rely on the ‘Core Assessment Program for Surgical Interventional Therapies in Parkinson’s
Disease’ (CAPSIT-PD) published in 1999 [1]. These criteria were primarily designed to facilitate
clinical research, harmonizing the cohorts of clinical trials. However, most of the indications provided
in the CAPSIT-PD document were introduced as guidance into the clinical practice of DBS centers
worldwide, being extremely useful in supporting the selection of candidates [2]. Twenty years later,
these indications could be considered both restrictive and out-of-date, because the knowledge on
PD progression, phenotyping, and genotyping has strongly evolved over the last 20 years. Indeed,
according to CAPSIT-PD, only 1.6% of PD subjects would be eligible for DBS, rising to 4.5% when
applying more flexible criteria [3].
Moreover, a growing number of studies have reported novel data on the outcome of DBS in the
short- and long-term follow-up and proposed predictors of DBS response [4,5]. However, evidence on
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how to improve and refine the selection process based on these insights for candidates to DBS is still
lacking. Finally, despite the consolidated efficacy of DBS in improving PD cardinal symptoms and
motor complications, the factors predicting a successful outcome on activities of daily living (ADL)
and quality of life (QoL) have been addressed only by a few studies so far [6].
Advances in understanding the heterogeneity of PD presentation, courses, phenotypes,
and genotypes impose a better identification of DBS candidates as a research priority. Additionally,
DBS invasiveness, cost, and the possibility of serious adverse events make it mandatory to predict
as accurately as possible the clinical outcome when informing the patients about their suitability
for surgery.
Here, we appraised the DBS pre-surgical assessment for PD starting from the original CAPSIT-PD
document and addressed the following topics which may impact on the selection process: early versus
delayed DBS; the evolution of the levodopa challenge test; the relevance of axial symptoms; new focus
on patient-centered outcome measures; the relevance of non-motor symptoms; and a new role for
genetics. Our main aim was to highlight current pitfalls and potentialities in the DBS selection process,
stimulating future randomized control trials (RCT) to address specific needs.
2. Early Versus Delayed DBS: How Early?
2.1. The Standard Rule
The CAPSIT-PD document recommended that a patient considered for interventional surgery
should have a diagnosis of idiopathic PD and a minimum disease duration of five years [1].
These requirements were developed to exclude people with atypical parkinsonism, given the absence
of benefits and the risk to harm patients with no idiopathic PD [7].
2.2. Pros and Cons
The concept of a five-year disease duration has been challenged upon the results of a large RCT
published in 2013 (the EARLY-STIM trial) [8]. In this trial demonstrating the superiority of subthalamic
(STN) DBS compared to medical therapy alone, patients were included when having a PD diagnosis of
≥4 years, and fluctuations or dyskinesia present for four years or less [8].
The EARLY-STIM trial endorsed a conceptual change about the use of DBS for PD favoring a
paradigm shift from DBS as the last therapeutic option for advanced disease stages toward an earlier
approach for patients experiencing motor complications. This paradigm change is based on three
relevant points: (1) the confirmation of DBS safety over the years, even in the long term; (2) the great
efficacy of DBS in improving the QoL of patients, even superior to levodopa alone [9]; (3) an earlier
intervention could preserve functional capacity. The evidence of efficacy provided by the EARLY-STIM
trial led the U.S. Food and Drug Administration (FDA) to extend the DBS indication to patients with a
four year PD diagnosis in the presence of at least four months of uncontrolled motor complications [10].
The EARLY-STIM trial has triggered discussion as to whether its findings should be translated into
clinical practice [11]. Firstly, the shorter disease duration at the time of surgery might pose the risks of
including subjects with atypical parkinsonism for which the five-year rule has been developed for
CAPSIT-PD. However, in the EARLY-STIM cohort, the mean disease duration of the surgically-treated
group was 7.3 ± 3.1 years and only three cases (0.8% of the cohort) were re-diagnosed as non-idiopathic
PD eight years after the first randomization and approximately 15 years after diagnosis [12]. However,
it should be noted that the issue of a shorter disease duration at the time of surgery might mirror a
greater and faster burden of disability which is also associated with specific genotypes associated
to PD, such as severe and complex glucocerobrosidase (GBA) gene variants [13], which have been
associated to poor DBS functional outcome [14].
A related matter is the difficulty in predicting the trajectory of disease progression at such an
early stage, either for more benign or rapidly progressing phenotypes [15], with the consequent risk of
referring to surgery patients whose motor fluctuations could remain mild for a long time, or vice-versa,
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those who may develop symptoms non-responsive to DBS and severely impacting ADL and QoL.
However, when looking carefully into the EARLY-STIM cohort, all patients had experienced either
motor or psychiatric disability due to PD. Accordingly, further analyses on this population have
demonstrated that STN-DBS was successful in improving freezing of gait (FoG) in OFF medication
condition [16], which affected 52% of the patients at baseline. Remarkably, behavioral complications
linked to dopaminergic overmedication had a better outcome in the neurostimulation group [17].
How early should DBS be considered in PD? A pilot open label study on 28 patients suggested
to consider DBS even earlier, before motor complications arose [18]. However, despite long term
follow-up data on the same cohort [19], the impact of early surgical intervention in such earlier stages
is still unknown and should be carefully interpreted including the risks we mentioned above but also a
presumptive neuroprotective effect [20]. Finally, it should be taken into account that DBS (STN-DBS
in particular) allows a reduction in dose of dopaminergic therapies in most patients [21]. Although
favoring the improvement of dyskinesia, the reduction in antiparkinsonian drugs could have role in
improving impulsive-compulsive behaviors and obsessive-compulsive and paranoid traits [22,23].
2.3. Recommendations
There is evidence for an earlier use of DBS as a treatment option to improve patients’ QoL and early
levodopa-responsive axial symptoms, while minimizing the psychiatric consequences of overtreatment.
Long-term results from the EARLY-STIM trial would allow the better defining of which PD features
are associated to a long-term successful outcome. However, there is not enough knowledge on how
early into the disease history DBS should be considered, given the paucity of published data and the
current lack of knowledge on how to predict disease progression and DBS response in such early
stages. We recommend considering each case singularly, according to the patient’s phenotype, age,
needs, and expectations in patients whose symptoms significantly impact ADL and QoL despite a
reasonable number of attempts to provide the best medical therapy.
3. The Evolution of the Levodopa Challenge Test
3.1. The Standard Rule
The second recommendation of CAPSIT-PD is dopaminergic responsiveness confirmed by a
levodopa/apomorphine challenge test (LCT). Accordingly, the test has to demonstrate at least a 33%
decrease in the Unified Parkinson’s Disease Rating Scale (UPDRS) part III score in the “defined-on
condition” (best therapeutic effect after medication agreed by patient and physician) compared to the
“defined-off condition” (at least 12 h after receiving the last medication dose).
3.2. Pros and Cons
The threshold of 33% for UPDRS improvement is considered relevant to rule out possible
misdiagnoses (i.e., identifying atypical parkinsonism for which DBS is not recommended). The LCT
is also important to inform the possible outcome of surgery, showing the likely extent of symptom
improvement after surgery, and to establish realistic expectations from DBS [24]. Indeed, it is generally
accepted that symptoms improving with levodopa are likely to respond to DBS [25]. However, there
are some exceptions and caveats to these widely accepted concepts. Firstly, levodopa-resistant tremor
represents one of the indications of DBS, even in the absence of disabling motor fluctuations [26,27],
given its excellent effect in controlling or even suppressing tremors, regardless of the deep nuclei
targeted [28].
Another relevant challenge related to the LCT is the cut-off of 33%. This value has been validated by
a study based on its ability to predict chronic levodopa responsiveness, with a positive predictive value
for the PD diagnosis of 88.6% [29]. Notably, the Movement Disorders Society (MDS)-sponsored UPDRS
scale introduced in 2008 has some differences in the scoring of the part-III (motor part), and a study
analyzing the MDS-UPDRS scores with the old UPDRS [30] ones after an acute LCT found an excellent
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correlation between the two scales, with the 30% UPDRS score variation used for predicting sustained
long-term levodopa response equivalent to 24% in MDS-UPDRS [31]. However, data from STN-DBS
clinical trials seems to indicate that an excellent response to levodopa (i.e., >50% UPDRS part-III
improvement) could be associated with a better DBS motor outcome [32]. A meta-analysis published in
2006 on the STN-DBS outcomes supports this hypothesis, demonstrating that the magnitude of decrease
in both UPDRS part-II and part-III scores exhibits a dose–response relationship with the presurgical
response to the levodopa challenge test [33]. However, it is unknown whether the magnitude of
response at the LCT may predict better ADL and Qol after DBS. Moreover, the relevance of axial
symptoms as a source of disability, their heterogenous response to dopaminergic therapies, and their
influence on the trajectory of the PD course put in light further considerations on the usefulness of the
presurgical LCT simplistically considered as a >30% motor response.
3.3. Recommendations
We recommend using LCT as a key tool to obtain relevant presurgical information on the patient’s
status and the possibility of improvement after DBS. However, the rule of UPDRS part-III improvement
>30% should not be strictly applied. Although patients affected by disabling dopa-resistant tremor
could represent an exception to this rule, improvement >50% can be associated with greater overall
benefit in most patients. The LCT response of disabling axial symptoms, such as FoG, is important and
should be weighted independently from the percentage UPDRS part-III total score improvement.
4. The Relevance of Axial Symptoms: How Sensitive Is Current Clinical Assessment?
4.1. The Standard Rule
The term ‘axial symptoms’ is commonly referred to as a group of PD motor features encompassing
gait impairment, postural instability, postural abnormalities, and speech disorders, especially dysarthria
and stuttering. These are a major source of disability because they are associated with reduced mobility,
communication difficulties, recurrent falls, and subsequent injuries [34]. Moreover, they are markers of
advanced disease and are often resistant to dopaminergic therapies or exhibit an heterogenous pattern
of response to levodopa [35]. There are no precise indications on how to consider these symptoms and
their pre-surgical response to levodopa in the clinical practice.
4.2. Pros and Cons
The evidence on the effect of DBS on axial symptoms is controversial. A meta-analysis published
in 2004 showed that one year after surgery, STN-DBS or globus pallidus pars interna (GPi) DBS
can improve gait and balance symptoms, with an effect size similar to the preoperative effects of
dopaminergic medication [36]. However, the improvement provided by DBS seems not sustained over
the years. Evidence for axial symptom progression, despite a good control of PD appendicular motor
symptoms, has been shown in open-label, long-term follow-up studies, although some extent of axial
improvement related to stimulation is reported in the first years after surgery [37–40].
The relevance of axial symptoms as a marker of disease progression was disclosed in a cohort
of 143 PD patients treated with STN-DBS [5], in whom axial disability during the follow-up period
was strongly associated with an increased risk of death (hazard ratio of 4.3), proving to be the most
accurate mortality predictor, even superior to the cognitive status.
Axial symptoms track disease progression and disability, therefore an accurate presurgical
evaluation of levodopa-responsiveness would be necessary for estimating the extent of response after
DBS. Indeed, worsening or amelioration after DBS of speech, posture and gait disorders is multifactorial
and depends upon clinical variables such as disease duration [16,41], the type of axial symptom (gait
often improves after DBS, speech may worsen as a stimulus-related side effect), their interplay with
dopaminergic medications [42,43], the brain target employed for DBS, the frequency [44,45] and
distribution of stimulation [46], and placement of active electrode contact [41].
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Levodopa-resistant axial symptoms are considered a relative contraindication for surgery [47];
however, the current pre-surgical clinical examination is unable to detect early axial signs which
may foster worse DBS outcomes. In particular, FoG evaluation poses great challenges, given the
episodic nature of this phenomenon and the complex relationship with dopaminergic medications.
Trunk postural abnormalities also represent a source of difficulty at the time of DBS selection (including
on which target to choose), because camptocormia and Pisa syndrome might be responsive to STN-DBS,
even with poor or no amelioration after LCT [48,49].
These difficulties which impact on the selection process might be overcome by integrating objective
evaluation involving kinematic analysis and wearable sensors to the pre-operative clinical examination.
Specifically, novel technological developments on wearable sensors for home-monitoring have the
potential to provide a measure of axial symptoms and their relation to levodopa intake in a naturalistic
way [50,51]. These technologies should be employed to detect early axial signs which might predict
worsening after DBS and assist the identification of the best candidates. Indeed, a study employing
kinematic assessment of gait demonstrated a correlation between presurgical levodopa response of
stride length and range of motion and FoG outcome after DBS [52].
4.3. Recommendations
The global burden of axial symptoms can be considered a proxy for disease stage because of their
correlation with disability and death. A fine-grained assessment of each axial symptom, the accurate
evaluation of their relationship with dopaminergic therapy, and the integration of technology outcome
measures into the clinical practice should favor a better understanding of candidates to DBS, with the
potential to predict their disease course and the probability to improve after DBS. Pending clinical trials
aiming at the evaluation of the effect of DBS on PD-related axial symptoms, we recommend to accurately
evaluate in clinical practice the presence, severity, and impact on patient’s daily life and independence
of axial symptoms before surgery, and discuss the weight of each symptom with the patient, clarifying
its poor, good, or indeterminate probability of improvement after DBS. Severe FoG and speech
issues, in particular, represent a potential challenge in the management of patients undergoing DBS,
while camptocormia and Pisa syndrome could have good chances of improvement and should not be
considered contraindications for DBS.
5. The Need for Patient-Centered Outcome Measures
5.1. The Standard Rule
From a regulatory point of view, the FDA and European Medicine Agency (EMA) request the
presence of motor fluctuations as a mandatory criterion for DBS indication in PD [10]. Reduction
in severity and frequency of motor fluctuations represents one of the most relevant achievements
obtained by DBS, which translates into the improvement of QoL revealed by randomized controlled
trials [8,53].
5.2. Pros and Cons
In CAPSIT-PD, it is recommended that the patients perform the self-reporting diary one week per
month during the three preoperative months, indicating the presence of four conditions: complete
OFF, partial OFF, complete ON, and ON with dyskinesias [1]. However, these measures are highly
subjective, and wrong or missed entries may occur in about one third of cases—also when using
electronic motor diaries [54]. That is, objective home-based quantification by wearable sensors of PD
motor symptoms [55], including FoG [56], should be explored carefully in patients considered for DBS,
also with respect to the predictive value of these measures. Indeed, when it comes to predicting the
outcome of DBS in PD and patient-centered outcome measures are employed, some discrepancies arise.
Patient-centered outcome measures are represented by QoL, evaluated by the validated Parkinson’s
Disease Questionnaire 39 (PDQ-39) [57] or by its short form (PDQ-8) [58], and ADL functioning or
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independence, typically measured by UPDRS part-II and the Schwab and England (S&E) scale [59].
The importance of measuring patient-centered outcomes relates to the discrepancy between the
judgment made in-clinic by the neurologist and the degree of satisfaction [60] and independence
obtained by the patient during daily life [54]. Two key factors may account for this discrepancy:
(1) motor symptoms observed by clinicians explain only a small part of the complex picture of PD,
which encompasses several non-motor symptoms; (2) the standardized tasks assessed during in-clinic
visits and the non-quantitative, non-continuous, non-ecologic in-clinic examinations may not represent
a comprehensive measure of the patient situation and condition during daily life. This last aspect is
true even when limiting the evaluation to motor symptoms, in particular episodic motor symptoms
such as FoG [61], which are not adequately captured during in-clinic standard assessments [54].
When it comes to analyzing determinants of improvement in QoL after STN DBS, a post-hoc
analysis of the EARLY-STIM trial found smaller QoL improvement at 24-months follow-up in patients
with better pre-surgical PDQ-39 scores [6]. Interestingly, patients with pre-surgical PDQ-39 scores ≤ 15
had no significant change in QoL following surgery. This finding is not meant to be caused by a
ceiling effect of STN-DBS to improve motor symptoms in the EARLY-STIM cohort, because the change
in QoL over the two years was independent of the severity of parkinsonian motor signs assessed
by UPDRS-III [8]. Accordingly, in another study analyzing a cohort of 85 PD patients treated with
DBS, the magnitude of motor symptom improvement with a pre-surgical LCT was only borderline
associated with improvement of QoL after DBS (p = 0.053) [62].
A systematic review [63] demonstrated that higher baseline QoL predicted larger QoL changes
after surgery in three out of four studies. The analysis of the 18 studies included in this review
yielded mixed results with respect to the predictive value of other clinical and demographical features.
There are two main explanations for such discrepant findings: (1) most of these studies were not
primarily designed to detect predictors of QoL change after DBS and results are influenced by the
main a priori hypothesis tested in each study; (2) factors contributing to QoL in PD include not only
motor disability but also non-motor symptoms [64], and the interplay between these domains might
be individualized and have a different weight in each subject. Moreover, among motor symptoms,
axial disability (and its response to therapies) might have a high impact, which has not been yet
explored carefully in regard to QoL or ADL outcome after DBS.
5.3. Recommendations
Future studies should be designed to capture predictors of QoL and ADL improvements after
DBS, taking into account the heterogeneity of the disease, the contribution of non-motor symptoms,
and the impact of axial symptoms. We recommend evaluating both the ADL and QoL of candidates
for DBS by means of validated scales (e.g., UPDRS part-II and PDQ-39 or PDQ-8) and carefully discuss
with patients the disease burden and their determinants. After surgery, these scales can inform more
than the in-clinic motor assessment about the clinical status of the patient and the impact of stimulation
on their functioning in daily life, guiding possible changes in stimulation parameters, medical therapy
or non-medical interventions, such as psychological support, physiotherapy, and emotional and
social stimulation.
6. The Complexity of PD Spectrum Integrated into the Selection Process: Relevance of
Non-Motor Symptoms
6.1. The Standard Rule
Despite the fact that DBS was developed to treat motor symptoms, the growing relevance given
to non-motor symptoms (NMS) in the last 15 years fostered investigations into the effect of DBS for
these features as well [65,66]. There are no indications nor clues so far on how to consider the presence
and burden of non-motor symptoms in PD candidates for DBS.
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6.2. Pros and Cons
A few studies have demonstrated the improvement of different NMS (cardiovascular, sleep/fatigue,
perceptual problems/hallucinations, gastrointestinal, urinary, and miscellaneous domains) six months
after surgery [65], which were maintained at 24 months for the sleep/fatigue, urinary and miscellaneous
domains [66], and at 36 months for the sleep domain [67]. These findings were confirmed in a small
cohort of young onset PD patients, for whom STN-DBS provided sustained improvement of the sleep
domain of the Non-Motor Symptoms Scale and Parkinson’s disease sleep scale-2 up to 24 months and
correlated to the decrease in dopamine-agonist medication [68].
Remarkably, change in NMS frequency and severity after STN-DBS is strongly correlated to the
improvement in QoL both in uncontrolled [66] and controlled studies [67,69] performed in the same
STN-treated cohort at different follow-up.
In the attempt to define profiles for the best DBS candidates which may encompass the complexity
of PD clinical spectrum and its heterogeneity, a new data-driven approach to PD, supported by
biomarkers and neuropathology, disclosed three different PD subtypes: mild-motor predominant,
intermediate, and diffuse malignant [70,71]. These three groups, defined based on the progression
of disability and mortality, differ in the presentation of motor and non-motor symptoms at onset,
in particular for the contribution of three types of NMS: cognitive impairment, rapid eye movement
sleep behavior disorder, and dysautonomia. When the same subtyping criteria were applied to a cohort
of STN-DBS patients at the time of the surgical selection, the mild phenotype seem to perform better
on ADL independence at the short and long-term follow-up compared to the malignant phenotype,
despite similar efficacy of stimulation on motor symptoms, fluctuations, and ambulatory capacity [72].
6.3. Recommendations
More efforts are needed to understand which NMS are predictors of good or poor outcome,
how different targets of DBS (STN or GPi) should be indicated to treat different NMS based on the
ability to decrease total LEDD and dopamine-agonists LEDD [17], or directly treat particular symptoms
by means of the stimulation of specific networks involved in pain or mood, apathy and attention [73].
We recommend to carefully assess the presence and severity of non-motor symptoms before surgery
and explain to the patients that when the disease burden is mainly driven by non-motor symptoms,
DBS might not be the best therapeutic option to consider.
7. A New Role for Genetics
7.1. The Standard Rule
One of the most remarkable advances in our understanding of PD pathogenesis in the last 20 years
is represented by genetics. The increasing power of genetic analyses led to the identification of several
chromosomal loci that cause or modulate the risk for PD [74]. Moreover, specific genetic mutations
have been associated to specific clinical features and different disease courses, which could have an
impact on the selection for DBS.
That is, only some evidence on the differential DBS response in different forms of monogenic PD
has been put forward, suggesting some differences in the magnitude of response [14,75–77]. However,
in this case there are no specific recommendations on the use of genetics in the clinical practice of
DBS centers.
7.2. Pros and Cons
The main advantage of knowing the genotype of a PD patient appraised for DBS is related to the
knowledge of disease evolution associated to a particular gene variant. However, despite the effort of
systematic reviews [76,77] and one meta-analysis [14], the small size of the cohorts reported and the
paucity of data on different gene variants and brain targets other than STN, do not allow researchers to
reach firm conclusions. For example, LRRK2-G2019S variant carriers, described in 44 out of 50 LRRK2
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subjects with DBS reported in the literature, show an excellent response to STN DBS, which is also
the most reported target [76]. G2019S is the most frequent LRRK2 variant and produces a phenotype
overlapping to late-onset, non-mutated PD with frequent presence of tremor and good response to
dopaminergic medications [78]. However, in three out of four reported cases with LRRK2-R1441G
variant, a mutation variant rarely found outside northern Spain, poor response to STN-DBS was
reported [76]. The paucity of data characterizing the phenotype of LRRK2-R1441G variant makes it
impossible to assume that the poor DBS outcome was due to more severe disease progression and
development of DBS resistant features. A similar issue applies to carriers of glucocerebrosidase (GBA)
gene variants which have a high prevalence of neuropsychiatric symptoms, especially impulsive
compulsive behavior and hallucinations, and a higher risk to develop early over disease course
cognitive disturbances [13]. Indeed, GBA-associated PD showed worse cognitive and functional
performances and lower reductions in dopaminergic medication after surgery [14]. However, it is
unknown which variants mostly contribute to this result. Remarkably, the risk of hallucinations and
cognitive impairment, as well as survival, differs across GBA subjects, being higher in subjects carrying
complex and severe variants [13,79].
7.3. Recommendations
Genetic testing is becoming accessible and affordable in clinical practice in many countries and
may be used to inform PD candidates for their suitability for DBS. Evidence is still weak to opt for
either endorsing DBS or not for a certain patient only relying on the genetic background, but in the
future it is probable that certain genotypes will be considered not suitable for DBS on the basis of their
improbability to benefit from the effects. To date, genetic testing of patients undergoing DBS might
be proposed in those manifesting specific phenotype features (e.g., rapid development of disability,
susceptibility to behavioral complications and hallucinations) consistent with particular gene variants,
such as severe GBA mutations, which may determine possible issues presented in the post-operative
follow-up (Figure 1).
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8. Conclusions
Advances in understanding both the complexity of PD and the effect of DBS in PD patients
have provided new evidence for a better stratification of patients and a more conscious use of this
therapeutic option.
It is critical to take into account that the multifaceted symptomatology of PD, encompassing motor,
non-motor, and behavioral issues, makes a candidate’s selection for advanced therapies a process
difficult to fit in fixed and precise borders. Additionally, the probability of improving or worsening
certain symptoms according to clinical trials (or to post-hoc analysis of trials) cannot capture the full
clinical complexity and heterogeneity of the PD clinical spectrum and should be used cautiously for
making a decision at a single level. To date, in addition to studies supporting a better comprehension
of pre-surgical predictors of DBS outcomes, we also need a shift in the statistical approach to improve
the decision-making from a group to an individual level.
In conclusion, the improvement in the stratification of PD patients according to their clinical
features and genetic background can inform the disease course, and more-in-depth knowledge on
patients most probable to benefit from DBS. A redefinition of CAPSIT-PD criteria for DBS should be
pursued based on the new knowledge gained on PD clinical spectrum and DBS long term follow-up
studies. This would allow surgical centers to be more accurate in predicting the outcome after functional
neurosurgery and choosing the best target for stimulation. We can now estimate the probability to
improve specific disabling symptoms and choose integrated approaches, combining stimulation of
specific targets according to patients’ issues (e.g., ventral STN for high non-motor burden [73]) with
other therapeutic options (e.g., rehabilitation), with the ultimate goal of improving ADL, mental
wellbeing, and eventually the QoL of PD patients. This viewpoint provided updated recommendations
for a more accurate and fine-grained assessment of PD patients considered as potential candidates
for DBS and highlighted the need for further studies to strengthen the evidence on predictors of
DBS outcomes at an individual level, encompassing the complex and multifaceted syndromic picture
of the disease and the new possibilities offered by validated clinical scales, technological devices,
and genetic analysis.
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